Use of vitamin D compounds to prevent transplant rejection

Details Use of vitamin D compounds to prevent transplant rejection Use of vitamin D compounds to prevent transplant rejection

1998-07-15

2000-06-06

Weddington, Kevin E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

9,10-seco- cyclopentanohydrophenanthrene ring system doai

A61K 3159

Patent

active

060718978

ABSTRACT:
A method of moderating transplant rejection in a transplant recipient comprising administering a dose of vitamin D compound effective to prevent transplant rejection is disclosed. Preferably, the recipient's susceptibility to opportunistic infections has not been compromised. Also preferably, the recipient has not suffered bone demineralization.

REFERENCES:
patent: 4749710 (1988-06-01), Truitt et al.
patent: 5374629 (1994-12-01), Calverley et al.
patent: 5387582 (1995-02-01), Hansen
patent: 5597815 (1997-01-01), DeLuca et al.
T. Cundy, et al., "The Use of Metabolites and Analogues of Vitamin D in Prospective Renal Transplant Recipients," Clin. Nephrol. 15(5) :240-245, 1981.
S.C. Jordan, et al., "1,25-Dihydroxyvitamin-D3 Prolongs Rat Cardiac Allograft Survival," Vitamin D Molecular, Cellular and Clinical Endocrinology, p. 335, 1988 (Abstract).
S.C. Jordan, et al., "1,25-Dihydroxyvitamin-D3 Prolongs Skin Graft Survival in Mice," Vitamin D Molecular, Cellular and Clinical Endocrinology, p. 347, 1988 (Abstract).
E. Lewin and K. Olgaard, "The In Vivo Effect of a New, In Vitro, Extremely Potent Vitamin D.sub.3 Analog KH1060 on the Suppression of Renal Allograft Rejection in the Rat," Calcif. Tissue Int. 54:150-154, 1994.
P. Veyron, et al., "Two Novel Vitamin D Analogues, KH 1060 and CB 966, Prolong Skin Allograft Survival in Mice," Trans. Immun. 1:72-76, 1993.
G. Babany, et al., "Evaluation of the in Vivo Dose-Response Relationship of Immunosuppressive Drugs Using a Mouse Heart Transplant Model: Application to Cyclosporine," J. Pharmac. Exp. Ther. 244(1) :259-262, 1988.
R. Bouillon, et al., "Structure-Function Relationships in the Vitamin D Endocrine System," Endocrine Rev. 16(2) :200-257, 1996.
B. Bourbigot, et al., "Bone Histology in Renal Transplant Patients Receiving Cyclosporin," The Lancet pp. 1048-1049, 1988.
V.A. Briner, et al., "Prevention of Cancellous Bone Loss but Persistence of Renal Bone Disease Despite Normal 1,25 Vitamin D Levels Two Years after Kidney Transplantation," Transplantation 59(10) :1393-1400, 1995.
C. Johnsson, et al., "Immunosuppression With the Vitamin D Analogue MC 1288 in Experimental Transplantation," Trans. Proc. 28 (2) :888-891, 1996.
B.A. Julian, et al., "Rapid Loss of Vertebral Mineral Density after Renal Transplantation," New Eng. J. Med. 325 (8) :544-550, 1991.
B.M. Kubak and C.D. Holt, "Infectious Complications of Kidney Transplantation and Their Management," Handbook of Kidney Transplantation, 2d Ed., G.M. Danovitch, Little, Brown and Company (Inc.), pp. 187-213, 1996.
J.M. Lemire, et al., "Prolongation of the Survival of Murine Cardiac Allografts by the Vitamin D.sub.3 Analogue 1,25-Dihydroxy-.increment..sup.16 -Cholecalciferol," Transplantation 54 (4) :62-63, 1992.
J.M. Lemire, et al., "1,25-Dihydroxy-24-OXO-16ene-Vitamin D3, a Renal metabolite of the Vitamin D Analog 1,25-Dihydroxy-16ene-vitamin D3, exerts Immunosuppressive Activity Equal to its Parent without causing Hypercalcemia in vivo," Endocrinology 135 (6) :2818-2821, 1994.

Affiliated with

Also associated with

Rating

Use of vitamin D compounds to prevent transplant rejection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of vitamin D compounds to prevent transplant rejection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of vitamin D compounds to prevent transplant rejection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2213693